Comment on Tanabe et al. Prediction of Sarcopenia Onset in Type 2 Diabetes Using Urinary Titin Levels: A Japanese Prospective Cohort Study. Diabetes Care 2025;48:1844–1849

We read with great interest the article on the prospective cohort study by Tanabe et al. (1), which demonstrated for the first time that baseline urinary titin levels independently predict future development of sarcopenia in individuals with type 2 diabetes, particularly with respect to declines in muscle strength such as grip strength. This finding provides a highly promising noninvasive biomarker for early identification of high-risk individuals and marks a significant step toward precision monitoring of muscle health. The authors’ work is pioneering and deserves strong recognition.